Déjà vu at Ampio Pharmaceuticals as its shares tumbled by 61% yesterday after it posted new data showing its osteoarthritis of the knee drug once again failed to hit its primary endpoint.
Shares of Ampio Pharmaceuticals were crushed this morning after the biotech acknowledged that its lead drug flunked a Phase III test for osteoarthritis. And the news comes just days after one of its drug subsidiaries was absorbed into a new biotech that will be called Aytu.
